Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06143046
Other study ID # mRNA-1345-P201
Secondary ID 2023-505359-37-0
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 15, 2023
Est. completion date February 18, 2026

Study information

Verified date May 2024
Source ModernaTX, Inc.
Contact Moderna Clinical Trials Support Center
Phone 1-877-777-7187
Email clinicaltrials@modernatx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date February 18, 2026
Est. primary completion date February 18, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Key Inclusion Criteria: Maternal Participants - Are adults =18 years to <40 years of age inclusive, at the time of signing the informed consent. - Will be 28 to 36 weeks pregnant at the time of vaccination (confirmed by an obstetric ultrasound report). - Intend to deliver at a maternity unit where study procedures can be performed. - Are willing and able to attend all study visits, to undergo all study procedures/or have their infant undergo all study procedures, and to comply with study requirements, including a means of communication (for example, phone, text message or email) with study site staff. - Have engaged with local antenatal care and will continue to do so through the remainder of their pregnancy. - Have had an antenatal obstetric ultrasound at =18 weeks of pregnancy or be willing to have an antenatal obstetric ultrasound at Screening if not already conducted. Specific inclusion criteria for Japanese pregnant women: - Japanese participants are defined as individuals born in Japan, with both parents and 4 grandparents who were born in Japan. Infant Participants - Have consent from infant participant's parent(s)/legally authorized representative (LAR) if required by local regulations. Key Exclusion Criteria: Maternal Participants - Acutely ill or febrile (temperature =38.0 degrees Celsius [?]/100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1. - Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of any mRNA vaccine or therapeutic or any components of an mRNA-1345 vaccine. - Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. - Have conditions in the current pregnancy or in previous pregnancies that may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. - Received or plans to receive any mRNA vaccine or COVID-19 vaccine within 4 weeks before or after Day 1 and/or any other nonstudy vaccine within 2 weeks before or after Day 1. - Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation. Infant Participants - Is a child who has been placed under the control or protection of an agency, organization, institution, or entity by the courts, the government, or a government body acting in accordance with powers conferred on them by laws and regulation (for example, foster care). This does not include a child who is adopted or has an appointed LAR. Other inclusion and exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
mRNA-1345
Sterile liquid for injection
Placebo
0.9% sodium chloride (normal saline) injection

Locations

Country Name City State
Canada Dalhousie University - 5820 University Ave Halifax Nova Scotia
Canada Sainte Justine Hospital Montréal Quebec
Canada Ottawa Hospital Ottawa Ontario
Canada Ottawa Hospital Civic Campus Ottawa Ontario
Canada Centre Hospitalier de l'Université Laval Quebec
Chile Clínica Universidad de los Andes Las Condes Región-MetropolitanadeSantiago
Chile Centro Internacional de Estudios Clínicos Recoleta Región-MetropolitanadeSantiago
Chile Red Hospital Clinico de la Universidad de Chile Santiago
Denmark Aarhus Universitetshospital Aarhus Central Jutland
Denmark Regionshospitalet Gødstrup Herning Central Jutland
Denmark Hvidovre Hospital Hvidovre Capital
Japan Shonan Kamakura General Hospital Kamakura-Shi Kanagawa
Japan Saitama City Hospital Saitama-Shi Saitama
Japan Center Hospital of the National Center for Global Health and Medicine Shinjuku-Ku Tokyo
Japan Saiseikai Yokohamashi Nanbu Hospital Yokohama Kanagawa
Panama Centro De Vacunacion Internacional, S.A. (Cevaxin) Ciudad De Panamá
Panama Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede La Chorrera Ciudad De Panamá
Panama Centro De Vacunacion Internacional, S.A. (Cevaxin) - David David Chiriquí
Panama CEVAXIN 24 de diciembre Panamá
Panama Instituto de Investigaciones Científicas Y Servicios de Alta Tecnología Asociación de Interés Panama Pueblo Nuevo
South Africa Josha Research Bloemfontein Free State
South Africa FAM-CRU Cape Town Western Cape
South Africa Bothe ke Bontle Health Services-316 Kuit st Pretoria Gauteng
South Africa Setshaba Research Centre Soshanguve Gauteng
South Africa WITS Clinical Research Site - PPDS Soweto Gauteng
South Africa Limpopo Clinical Research Initiative Thabazimbi Limpopo
United Kingdom Royal Bournemouth Hospital Bournemouth Dorset
United Kingdom Cardiff & Vale University Health Board-PPDS Cardiff South Glamorgan
United Kingdom Glasgow Clinical Research Facility - PPDS Glasgow
United Kingdom St George's Hospital London Surrey
United Kingdom The Royal Free Hospital London Middlesex
United Kingdom The Royal London Hospital London London, City Of
United Kingdom Southampton General Hospital Southampton Hampshire
United States DM Clinical Research - Birthing Center of New York - ERN - PPDS Brooklyn New York
United States Velocity Clinical Research - Covington - PPDS Covington Louisiana
United States SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS Dothan Alabama
United States Matrix Clinical Research - Gardena Gardena California
United States Velocity Clinical Research (Grand Island - Nebraska) - PPDS Grand Island Nebraska
United States Boeson Research GTF - Great Falls - ERN - PPDS Great Falls Montana
United States Velocity Clinical Research (Hastings - Nebraska) - PPDS Hastings Nebraska
United States DM Clinical Research - Bellaire - ERN - PPDS Houston Texas
United States Matrix Clinical Research - Huntington Park Huntington Park California
United States Clinical Research Prime - ClinEdge - PPDS Idaho Falls Idaho
United States Boeson Research KAL - Kalispell - ERN - PPDS Kalispell Montana
United States Maximos OB/GYN League City Texas
United States Applied Research Center of Arkansas - ClinEdge - PPDS Little Rock Arkansas
United States Matrix Clinical Research, Inc - Corporate Office Los Angeles California
United States Boeson Research MSO - Missoula - ERN - PPDS Missoula Montana
United States Velocity Clinical Research (Norfolk - Nebraska) - PPDS Norfolk Nebraska
United States Abby's Research Institute Phoenix Arizona
United States Clinical Research Prime - ClinEdge - Rexburg - PPDS Rexburg Idaho
United States Saginaw Valley Medical Research Group LLC Saginaw Michigan
United States Maternal Fetal Diagnostics Center Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
ModernaTX, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Chile,  Denmark,  Japan,  Panama,  South Africa,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Maternal Participants with Solicited Local and Systemic Adverse Reactions (ARs) Up to Day 7 (7 days post vaccination)
Primary Number of Maternal Participants with Unsolicited Adverse Events (AEs) Up to Day 28 (28 days post vaccination)
Primary Number of Maternal Participants with Medically-Attended AEs (MAAEs) Day 1 to Month 6 (6 months postdelivery)
Primary Number of Maternal Participants with Adverse Events of Special Interest (AESIs) Day 1 to Month 12 (12 months postdelivery)
Primary Number of Maternal Participants with Serious Adverse Events (SAEs) Day 1 to Month 12 (12 months postdelivery)
Primary Number of Maternal Participants with AEs Leading to Discontinuation Day 1 to Month 12 (12 months postdelivery)
Primary Number of Maternal Participants With Pregnancy Outcomes Pregnancy outcomes will include stillbirth, live birth, vaginal delivery, and cesarean section delivery. Day 1 to Month 12 (12 months postdelivery)
Primary Number of Infant Participants with MAAEs Day 1 (birth) to Month 12
Primary Number of Infant Participants with AESIs Day 1 (birth) to Month 12
Primary Number of Infant Participants with SAEs Day 1 (birth) to Month 12
Primary Number of Infant Participants With Birth Outcomes Birth outcomes will include gestational age and anthropometric measurements. Day 1 (birth) to Month 12
Secondary Geometric Mean Titer (GMT) of Serum RSV-A and RSV-B Neutralizing Antibodies in Maternal Participants Day 1, Day 29, delivery, and Month 6 (6 months postdelivery)
Secondary Geometric Mean Concentration (GMC) of Serum RSV-F Binding Antibodies in Maternal Participants Day 1, Day 29, delivery, and Month 6 (6 months postdelivery)
Secondary Geometric Mean Fold-Rise (GMFR) of Postbaseline/Baseline Neutralizing Antibody Titers and Binding Antibody Concentrations in Maternal Participants Day 29, delivery, and Month 6 (6 months postdelivery)
Secondary Percentage of Maternal Participants With =4-fold Increase From Baseline in Neutralizing Antibody Titers and Binding Antibody Concentrations Baseline up to Month 6 (6 months postdelivery)
Secondary GMT of Serum RSV-A and RSV-B Neutralizing Antibodies in Infant Participants Day 1 (birth), and Months 2, 6, and 12
Secondary GMC of Serum RSV-F Binding Antibodies in Infant Participants Day 1 (birth), and Months 2, 6, and 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04528719 - A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive Phase 1
Terminated NCT02508194 - A Study to Evaluate the Efficacy of MEDI7510 in Older Adults Phase 2
Active, not recruiting NCT06060457 - A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age Phase 3
Terminated NCT01757496 - Cough Assist in Bronchiolitis N/A
Completed NCT00100373 - RSV Challenge in Healthy Adults N/A
Completed NCT03524118 - Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Phase 1/Phase 2
Active, not recruiting NCT05572658 - Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
Recruiting NCT06067230 - A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults Phase 3
Completed NCT00246480 - RSV Disease in the Elderly
Active, not recruiting NCT06097299 - A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Phase 2
Completed NCT00889070 - Respiratory Events Among Premature Infants N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Completed NCT05559905 - Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Phase 2
Active, not recruiting NCT05127434 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age Phase 2/Phase 3
Terminated NCT04978337 - A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Phase 2
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT02472548 - A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Phase 1
Completed NCT01734668 - Sofia RSV FIA Field Study N/A
Completed NCT01562938 - MEDI-557 Adult Dosing Phase 1
Recruiting NCT06325657 - A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants Phase 3